Randomized Phase III Trial of Amrubicin Versus Carboplatin Plus Etoposide in Elderly Patients With Extensive-Disease Small-Cell Lung Cancer.
Phase of Trial: Phase III
Latest Information Update: 18 May 2016
At a glance
- Drugs Amrubicin (Primary) ; Carboplatin; Etoposide
- Indications Small cell lung cancer
- Focus Therapeutic Use
- Sponsors Sumitomo Dainippon Pharma
- 08 Oct 2010 Results have been presented at the 35th Congress of the European Society for Medical Oncology (ESMO).
- 07 Jul 2010 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 10 Dec 2008 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History